Hyderabad/Mumbai, Maharashtra, India, July 2025 – Cohance Lifesciences Ltd. , a leading integrated Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Mr. Yann D’Herve as Chief Executive Officer of the company’s CDMO business. The business operates as a fully integrated, innovation-led platform serving global pharmaceutical companies, including capabilities in small molecule APIs, Antibody Drug Conjugates (ADCs), and Nucleic Acid Chemistry.
Effective August 1, 2025, D’Herve’s appointment brings a strong track record of senior-level leadership to Cohance. He has a rich and diverse background spanning multiple business functions and geographies. His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors.
Most recently, D’Herve served as Senior Vice President and General Manager of Evonik’s Healthcare division, where he was responsible for 2,600 employees across nine manufacturing sites, with full P&L responsibility, including for the company’s CDMO business. Prior to that, he held several senior roles at Evonik, including as Vice President of Sales and Services, and divisional leadership assignments. He began his career in manufacturing, gaining hands-on experience in production and operations. Mr. D’Herve holds an MBA from Université de Picardie Jules Verne in Amiens, and a Master’s in Chemistry from CPE, Lyon, France.
On the appointment of Mr. Yann D’Herve, Mr. Vivek Sharma, Executive Chairman of Cohance Lifesciences Ltd., commented, “We are delighted to welcome Yann to Cohance. His deep experience in leading multifaceted global pharmaceutical services businesses will be of tremendous benefit in accelerating the growth of our CDMO platform.”
Mr. Yann D’Herve shared, “I am excited to join a growing CDMO with differentiated technologies such as ADCs and oligonucleotides and a strong global asset base. I look forward to working with the Cohance team to support the development and manufacturing of life-saving drugs for our partners.”
About Cohance Lifesciences
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) is an integrated, technology-driven global CDMO platform committed to advancing therapeutics for a healthier world.
Our rebranding from Suven Pharma to Cohance marks a bold new chapter—one that reflects our expanded vision and sharpened focus on collaboration and innovation.
The name Cohance captures our purpose: to Collaborate with global innovators and Enhance their molecules, helping bring transformative solutions to patients and consumers worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
